CITIC Securities: RAS Drugs Unlock New Cancer Treatment Landscape

CITIC Securities published a research report highlighting the progress in RAS-targeted cancer drugs, which aim to unlock previously undruggable targets. RAS is a family of oncogenes, including KRAS, NRAS, and HRAS, with KRAS being the most critical in human tumors. The field has advanced from targeting the G12C mutation to developing G12D, Pan-KRAS, and Pan-RAS(ON) inhibitors, with multiple clinical trials underway. At the 2026 ASCO conference, RMC-6236 showed positive results in a Phase III study for second-line metastatic pancreatic cancer, nearly doubling median overall survival compared to chemotherapy. Chinese companies are actively pursuing G12D, Pan-RAS, and Pan-KRAS programs. The report underscores the growing clinical and market potential of RAS-targeted therapies.

Global Impact

Economically, the RAS drug market could become a multi-billion-dollar segment, reshaping oncology spending and creating winners among first-movers. Technologically, the progress validates novel drug design approaches for previously undruggable targets, potentially accelerating other hard-to-drug targets.